Britain’s biotech firms now have a code of conduct designed to prevent them
from overhyping the progress of experimental drugs. Published this week by the
BioIndustry Association (BIA), the code was drafted in the wake of a damaging
scandal last year
(This Week, 4 July 1998, p 20).
From now on, companies must
have their scientific and clinical progress audited by external experts. Failure
to comply could mean expulsion from the BIA.
More from New Scientist
Explore the latest news, articles and features
Physics
A quantum state that lasts forever may finally be within our grasp
Features
Life
Walking shark found in Papua New Guinea is new to science
News
Mind
Autism may have two distinct subtypes that vary by brain activity
News
Environment
Arctic Ocean reaches tipping point that could be dire for marine life
News
Popular articles
Trending New Scientist articles
1
Sperm have been made magnetic to allow IVF inside the body
2
Fully autonomous drones have killed human soldiers for the first time
3
Autism may have two distinct subtypes that vary by brain activity
4
We may have finally solved cosmology's chicken-or-the-egg problem
5
Has the answer to life's origins been hiding in our cells all along?
6
A quantum state that lasts forever may finally be within our grasp
7
Global map reveals the vast scale of underground fungal networks
8
Vaping after quitting smoking is linked to lung cancer
9
Technology is changing our perspective on nature – at every scale
10
The relationship recession is even bigger for Gen Z than we thought
